Vascepa, a prescription omega-3 fatty acid medication for the treatment of very high triglyceride blood levels, has had its original patent expire. According to DrugPatentWatch.com, the compound ezetimibe's original US patent for ' Vascepa (generic name: icosapent ethyl)' expired in 2026 [1].
Generic versions of Vascepa are expected to become available as a result of this patent expiration. As generic versions become available, they may significantly lower the price of the medication, making it more accessible to patients [2].
DrugPatentWatch.com provides a database of pharmaceutical patents, including their expiration dates, which can be used to track the availability of generic medications [3].
Sources:
[1] DrugPatentWatch.com, Vascepa (generic name: icosapent ethyl).
[2] DrugPatrol, Vascepa, available at: (https://www.drugpatrol.com/vascepa)
[3] (https://www.drugpatentwatch.com/)